Alpine Immune Sciences Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 142

Employees

  • Stock Symbol
  • ALPN

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $64.44
  • (As of Thursday Closing)

Alpine Immune Sciences General Information

Description

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Contact Information

Formerly Known As
N30 Pharmaceuticals, Inc, Nivalis Therapeutics, Inc
Ownership Status
Publicly Held
Financing Status
Pending Transaction (M&A)
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 188 East Blaine Street
  • Suite 200
  • Seattle, WA 98102
  • United States
+1 (206) 000-0000

Alpine Immune Sciences Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alpine Immune Sciences Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$64.44 $64.46 $6.71 - $64.57 $4.22B 65.6M 2.14M -$0.64

Alpine Immune Sciences Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 924,050 924,050 104,202 258,358
Revenue 58,876 58,876 30,064 23,443
EBITDA (43,259) (43,259) (57,647) (49,243)
Net Income (32,184) (32,184) (57,762) (50,333)
Total Assets 379,852 379,852 286,686 255,900
Total Debt 9,914 9,914 14,221 19,628
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alpine Immune Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alpine Immune Sciences‘s full profile, request access.

Request a free trial

Alpine Immune Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Alpine Immune Sciences‘s full profile, request access.

Request a free trial

Alpine Immune Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein
Pharmaceuticals
Seattle, WA
142 As of 2023
00000
00.00 0000-00-00
000000&0 00000

000000

prehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Exce
000000000000000
Tarrytown, NY
00000 As of 0000
00.000
000000000000 00.000

000000

olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000000000000
Austin, TX
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alpine Immune Sciences Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regeneron Pharmaceuticals Formerly VC-backed Tarrytown, NY 00000 00.000 000000000000 00.000
Shattuck Labs Formerly VC-backed Austin, TX 00 00000 00000000 00000
Xencor Formerly VC-backed Monrovia, CA 000 00000 00000000 00000
Zymeworks Formerly VC-backed Vancouver, Canada 000 00000 000000000000
MacroGenics Formerly VC-backed Rockville, MD 000 00000 000000000 00000
You’re viewing 5 of 5 competitors. Get the full list »

Alpine Immune Sciences Executive Team (13)

Name Title Board Seat Contact Info
Mitchell Gold MD Chief Executive Officer & Chairman
Stanford Peng Ph.D Executive & President
Paul Rickey Chief Financial Officer and Senior Vice President
Christina Yi Chief Technology Officer
Martin Fuhs Chief Accounting Officer & Vice President, Finance
You’re viewing 5 of 13 executive team members. Get the full list »

Alpine Immune Sciences Board Members (9)

Name Representing Role Since
Christopher Peetz Self Board Member 000 0000
James Topper Ph.D Frazier Healthcare Partners Board Member 000 0000
Mitchell Gold MD Alpine Immune Sciences Chief Executive Officer & Chairman 000 0000
Natasha Hernday Self Board Member 000 0000
Peter Thompson MD OrbiMed Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Alpine Immune Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alpine Immune Sciences Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Nivalis Therapeutics 24-Jul-2017 0000000000 0000 Biotechnology 00000000
To view Alpine Immune Sciences’s complete acquisitions history, request access »

Alpine Immune Sciences ESG

Risk Overview

Risk Rating

Updated January, 10, 2023

29.73 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,173

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 909

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 401

Rank

00.00

Percentile

To view Alpine Immune Sciences’s complete esg history, request access »

Alpine Immune Sciences FAQs

  • When was Alpine Immune Sciences founded?

    Alpine Immune Sciences was founded in 2015.

  • Who is the founder of Alpine Immune Sciences?

    Michael Kornacker Ph.D and Ryan Swanson are the founders of Alpine Immune Sciences.

  • Who is the CEO of Alpine Immune Sciences?

    Mitchell Gold MD is the CEO of Alpine Immune Sciences.

  • Where is Alpine Immune Sciences headquartered?

    Alpine Immune Sciences is headquartered in Seattle, WA.

  • What is the size of Alpine Immune Sciences?

    Alpine Immune Sciences has 142 total employees.

  • What industry is Alpine Immune Sciences in?

    Alpine Immune Sciences’s primary industry is Pharmaceuticals.

  • Is Alpine Immune Sciences a private or public company?

    Alpine Immune Sciences is a Public company.

  • What is Alpine Immune Sciences’s stock symbol?

    The ticker symbol for Alpine Immune Sciences is ALPN.

  • What is the current stock price of Alpine Immune Sciences?

    As of 18-Apr-2024 the stock price of Alpine Immune Sciences is $64.44.

  • What is the current market cap of Alpine Immune Sciences?

    The current market capitalization of Alpine Immune Sciences is $4.22B.

  • What is Alpine Immune Sciences’s current revenue?

    The trailing twelve month revenue for Alpine Immune Sciences is $58.9M.

  • Who are Alpine Immune Sciences’s competitors?

    Regeneron Pharmaceuticals, Shattuck Labs, Xencor, Zymeworks, and MacroGenics are competitors of Alpine Immune Sciences.

  • What is Alpine Immune Sciences’s annual earnings per share (EPS)?

    Alpine Immune Sciences’s EPS for 12 months was -$0.64.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »